Stabilizing formulations for inhalable powders of an adenovirus 35-vectored tuberculosis (TB) vaccine (AERAS-402)

Vaccine

Volumn 28, Issue 27, 2010, Pages 4369-4375

  Jin, Tom H ^a   Tsao, Eric ^a   Goudsmit, Jaap ^b   Dheenadhayalan, Veerabadran ^a   Sadoff, Jerald ^a  

^a Aeras Global TB Vaccine Foundation   (United States)

^b CRUCELL HOLLAND BV   (Netherlands)

Author keywords

Formulations; Spray drying; Tuberculosis; Vaccine

Indexed keywords

ADENOVIRUS VECTOR; AERAS 402; BCG VACCINE; CYCLODEXTRIN; DEXTRAN; LEUCINE; MANNITOL; POVIDONE; SUCROSE; TREHALOSE; UNCLASSIFIED DRUG;

ADENOVIRUS; ADENOVIRUS 35; AEROSOL; ARTICLE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRY POWDER; HYDROPHOBICITY; MASS IMMUNIZATION; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; THERMODYNAMICS; VACCINE PRODUCTION; VIRUS SURVIVAL; WATER ABSORPTION;

ADENOVIRIDAE; CELL LINE; CHEMISTRY, PHARMACEUTICAL; GENETIC VECTORS; HUMANS; TUBERCULOSIS VACCINES;

EID: 77952740850     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.04.059     Document Type: Article

References (51)

1. Fine P.E.M., Carneiro I.A.M., Milstein J.B., and Clements C.J. Issues relating to the use of BCG in immunization programs (1999), WHO, Geneva V&B/99.23
2. Colditz G.A., Brewer T.F., Berkey C.S., Wilson M.E., Burdick E., Fineberg H.V., et al. Efficacy of BCG vaccine in the prevention of Tuberculosis. J Am Med Assoc 271 March (2) (1994) 698-702
3. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis: emergency update 2008. WHO/HTM/TB/2008.402.
4. World Health Organization. Global tuberculosis control - epidemiology, strategy, financing. WHO/HTM/TB/2009.411.
5. Santosuosso M., McCormick S., Zhang X.Z., Zganiacz A., and Xing Z. Intranasal boosting with an adenovirus-vectored vaccine markedly enhances protection by parenteral Mycobacterium bovis BCG immunization against pulmonary tuberculosis. Infect Immun 74 August (8) (2006) 4634-4643
6. Skeiky Y.A., and Sadoff J.C. Advances in tuberculosis vaccine strategies. Nat Rev Microbiol 4 June (6) (2006) 469-476
7. Barker L.F., Brennan M.J., Rosenstein P.K., and Sadoff J.C. Tuberculosis vaccine research: the impact of immunology. Curr Opin Immunol 21 June (3) (2009) 331-338
8. McShane H., Pathan A.A., Sander C.R., Goonetilleke N.P., and Fletcher H.A. Hill AVS Boosting BCG with MVA85A: the first candidate subunit vaccine for tuberculosis in clinical trials. Tuberculosis 85 January-March (1-2) (2005) 47-52
9. Magalhaes I., Sizemore D.R., Ahmed R.K., Mueller S., Wehlin L., Scanga C., et al. rBCG induces strong antigen-specific T cell responses in rhesus macaques in a prime-boost setting with an adenovirus 35 tuberculosis vaccine vector. Plos ONE 3 November (11) (2008) 1-8
10. Radošević K., Wieland C.W., and Rodriguez A. Protective immune responses to a recombinant adenovirus type 35 tuberculosis vaccine in two mouse strains: CD4 and CD8 T-cell epitope mapping and role of gamma interferon. Infect Immun 75 August (8) (2007) 4105-4115
11. Barouch D.H., and Nabel G.J. Adenovirus vector-based vaccines for human immunodeficiency virus type 1. Hum Gene Ther 16 Feburary (2) (2005) 149-156
12. Stefan K., Wouter K., Mieke S., Jan W.G., Germaine P., Niels H., et al. Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector. AIDS 18 May (8) (2004) 1213-1216
13. Nanda A., Lynch D.M., Goudsmit J., Lemckert A.A.C., Ewald B.A., Sumida S.M., et al. Immunogenicity of recombinant fiber-chimeric adenovirus serotype 35 vector-based vaccines in mice and rhesus monkeys. J Virol 79 November (22) (2005) 14161-14168
14. Abel B., Tameris M., Mansoor N., Gelderbloem S., Hughes J., Abrahams D., et al. The novel TB vaccine, AERAS-402, induces a robust and polyfunctional CD4 T cell response, and a CD8 T cell response, in healthy adults. Am J Respir Crit Care Med (2010) (Accepted on Feb 18, 2010)
15. Patton J. Breathing life into protein drugs. Nat Biotechnol 16 February (2) (1998) 141-143
16. Bellanti J.A., Zeligs B.J., Mendez-Inocencio J., Garcia-Garcia M.L., Islas-Romero R., Omidvar B., et al. Immunologic studies of specific mucosal and systemic immune responses in Mexican school children after booster aerosol or subcutaneous immunization with measles vaccine. Vaccine 22 March (9-10) (2004) 1214-1220
17. Bennett J.V., de Castro J.F., Valdespino-Gomez J.L., Garcia-Garcia M.D., Islas-Romero R., Echaniz-Aviles G., et al. Aerosolized measles and measles-rubella vaccines induce better antibody booster responses than injected vaccine: randomized trials in Mexican schoolchildren. Bull WHO 80 November (10) (2002) 806-812
18. Wong Y.L., Sampson S., Germishuizen W.A., Goonesekera S., Caponetti G., Sadoff J., et al. Drying a tuberculosis vaccine without freezing. PNAS 104 February (8) (2007) 2591-2595
19. Chew N.Y.K., and Chan H.K. Effect of powder polydispersity on aerosol generation. J Pharm Pharm Sci 5 May-August (2) (2002) 162-168
20. Timsina M.P., Martin G.P., Marriott C., Ganderton D., and Yianneskis M. Drug delivery to the respiratory tract using dry powder inhalers. Int J Pharm 101 January (1-2) (1994) 1-13
21. Staniforth J.N., Rees J.E., Lai F.K., and Hersey J.A. Inter-particle forces in binary and ternary ordered powder mixes. J Pharm Pharmacol 34 March (3) (1982) 141-145
22. Ameri M., and Maa Y.F. Spray drying of biopharmaceuticals: stability and process considerations. Dry Technol 24 July (6) (2006) 763-768
23. Maa Y.F., Nguyen P.A., Swwwney T.D., Shire S.J., and Hsu C.C. Protein inhalation powder: spray drying vs. spray drying. Pharm Res 16 February (2) (1999) 249-254
24. Chen D., Maa Y.F., and Haynes J. Needle-free epidermal powder immunization. Expert Vaccine Rev 1 October (3) (2002) 265-276
25. Broadhead J., Rouan S., and Rhodes C. The spray drying of pharmaceuticals. Drug Dev Ind Pharm 18 July (11-12) (1992) 1169-1206
26. Dilraj A., Cutts F.T., de Castro J.F., Wheeler J.G., Brown D., Roth C., et al. Response to different measles vaccine strains given by aerosol and subcutaneous routes to schoolchildren: a randomized trial. Lancet 355 March (9206) (2000) 798-803
27. Dilraj A., Sukhoo R., Cutts F.T., and Bennett J.V. Aerosol and subcutaneous measles vaccine: measles antibody response 6 years after revaccination. Vaccine 25 May (21) (2007) 4170-4174
28. Philip V.A., Mehta R.C., Mazumder M.K., and DeLuca P.P. Effect of surface treatment on the respirable fractions of PLGA microspheres formulated for dry powder inhalers. Int J Pharm 151 May (2) (1997) 165-174
29. Chan H.K., Clark A., Gonda I., Mumenthaler M., and Hsu C. Spray dried powders and powder blends of recombinant human deoxyribonuclease (rhDNase) for aerosol delivery. Pharm Res 14 April (4) (1997) 431-437
30. Martonen T., and Katz I. Deposition patterns of polydisperse aerosols within human lungs. J Aerosol Med 6 March(4) (1993) 251-274
31. Chew N.Y.K., Bagster D.F., and Chan H.K. Effect of particle size, air flow and inhaler device on the aerosolisation of disodium cromoglycate powders. Int J Pharm 206 September (1-2) (2000) 75-83
32. Broadhead J., Rouan S., Hau I., and Rhodes C. The effect of process and formulation variables on the properties of spray dried beta-galactosidase. J Pharm Pharmacol 46 June (6) (1994) 458-467
33. Tzannis S.T., and Prestrelski S.J. Moisture effects on protein-excipient interactions in spray-dried powders. Nature of destabilizing effects of sucrose. J Pharm Sci 88 June (3) (2000) 360-370
34. Burger J.L., Cape S.P., Braun C.S., McAdams D.H., Best J.A., Bhagwat P., et al. Stabilizing formulations for inhalable powders of live-attenuated measles virus vaccine. J Aeros Med Pulmon Drug Deliv 21 March (1) (2008) 25-34
35. Corbanie E.A., Remon J.P., Reeth K.V., Landman W.J.M., van Eck J.H.H., and Vervaet C. Spray drying of an attenuated live Newcastle disease vaccine virus intended for respiratory mass vaccination of poultry. Vaccine 25 November (49) (2007) 8306-8317
36. Broadhead J., Rouan S.K., Hau I., and Rhodes C.T. The effect of process and formulation variables on the properties of spray-dried beta-galactosidase. J Pharm Pharmacol 46 June (6) (1994) 458-467
37. Labrude P., Rasolomanana M., Vigneron C., Thirion C., and Chaillot B. Protective effect of sucrose on spray drying of oxyhemoglobin. J Pharm Sci 78 March (3) (1989) 223-239
38. Bosquillon C., Lombry C., Preat V., and Vanbever R. Comparison of particle sizing techniques in the case of inhalation dry powders. J Pharm Sci 90 December (12) (2001) 2032-2041
39. Glover W., Chan H.K., Eberl S., Daviskas E., and Anderson S. Lung deposition of mannitol powder aerosol in healthy subjects. J Aerosol Med 19 Winter (4) (2006) 522-532
40. Costantino H.R., Andya J.D., Nguyen P.A., Dasovich N., Sweeney T.D., Shire S.J., et al. Effect of mannitol crystallization on the stability and aerosol performance of a spray-dried pharmaceutical protein, recombinant humanized anti-IgE monoclonal antibody. J Pharm Sci 87 June (11) (2000) 1406-1411
41. Daviskas E., Anderson S.D., Brannan J.D., Chan H.K., Eberl S., and Bautovich G. Inhalation of dry-powder mannitol increases mucociliary clearance. Eur Respir J 10 November (11) (1997) 2449-2454
42. Daviskas E., Anderson S.D., Eberl S., Chan H.K., and Bautovich G. Inhalation of dry powder mannitol improves clearance of mucus in patients with bronchiectasis. Am J Respir Crit Care Med 159 June (6) (1999) 1843-1848
43. Daviskas E., Anderson S.D., Eberl S., Chan H.K., and Young I.H. The 24-h effect of mannitol on the clearance of mucus in patients with bronchiectasis. Chest 119 February (2) (2001) 414-421
44. Daviskas E., Anderson S.D., and Gomes K. Inhaled mannitol for the treatment of mucociliary dysfunction in patients with bronchiectasis - effect on lung function. Respirology 10 January (1) (2005) 46-56
45. Anderson S.D., Brannan J., Spring J., Spalding N., Rodwell L.T., Chan K., et al. A new method for bronchial provocation testing in asthmatic subjects using a dry powder of mannitol. Am J Resir Crit Care Med 156 September (3) (1997) 758-765
46. Imamura K., Iwai M., Ogawa T., Sakiyama T., and Nakanishi K. Evaluation of hydration states of protein in freeze-dried amorphous sugar matrix. J Pharm Sci 90 December (12) (2001) 1955-1963
47. Mahlin D., Berggren J., Gelius U., Engström S., and Alderborn G. The influence of PVP incorporation on moisture-induced surface crystallization of amorphous spray-dried lactose particles. Int J Pharm 321 September (1-2) (2006) 78-85
48. Zhang J., and Zografi G. Water vapor absorption into amorphous sucrose-poly(vinyl pyrrolidone) and trehalose-poly(vinyl pyrrolidone) mixtures. J Pharm Sci 90 September (9) (2001) 1375-1385
49. Tracy P.H., Hetrick J.H., and Karenke W.A. Effect of spraying pressure and orifice size on the physical characteristics and keeping quality of spray-dried whole milk. J Dairy Sci 34 June (6) (1951) 583-592
50. Rochelle C., and Lee G. Dextran or hydroxyethyl starch in spray-freeze-dried trehalose/mannitol microparticles intended as ballistic particulate carriers for proteins. J Pharm Sci 96 February (9) (2007) 2296-2309
51. Finlay W.H., Lange C.F., King M., and Speert D.P. Lung delivery of aerosolized dextran. Am J Respir Crit Care Med 161 January (1) (2000) 91-97